And Then There Were Five: Roche's Tecentriq Joins Europe I-O Race
The latest approvals for the Swiss major's PD-1/L1 inhibitor in both bladder and lung cancer will boost revenues of the drug which may be the last to market in Europe but not the least.
You may also be interested in...
AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.